The diabetes pandemic is currently among the most challenging non-communicable disease threats to public health. It is estimated that 382 million people worldwide have diabetes and the majority will likely die from cardiovascular disease. Diabetes is an independent risk factor for atherosclerotic cardiovascular disease as well as heart failure, with a 5-fold increased risk of heart failure in women with diabetes and a 2.4-fold increased risk in men. [1] [2] [3] In patients with diabetes, the prevalence of heart failure is between 10 to 22%, 4 times higher than that of the general population. 2 The degree of glycemic control in patients with diabetes has been demonstrated to be associated with the risk of atherosclerotic cardiovascular disease and new onset heart failure. 1, 4 It has been a widely held belief that lowering HbA1c levels with glucoselowering medications in patients with diabetes would result in clinical benefits, including the reduction of atherosclerotic cardiovascular events. Lowering of the HbA1c levels by glucoselowering medications in patients with diabetes mellitus has been used as a surrogate measure of their benefit including the potential to reduce cardiovascular risk by clinicians, guideline writing groups, and regulators. 5 There is however little evidence from randomized clinical trials of substantial cardiovascular risk reduction with improved glycemic control in type 2 diabetes. o owe we weri ri rin ng ng m m med ed edicat at atio io ion ns in patients with diabetes m me mell litus has been us u u ed d a a as s s a a surrogate measure of h h hei i ir r benefit in ncl cl clud ud din ng g g th th he e po po pote te ent ntia ia al l to to re e educ ce card d dio o ova a asc sc cul ula a ar ri risk sk k b b by y cl cl lin inic icia ia ans ns, , gu gu uid id del el elin in i e e e wr wr rit i i i ing gr grou ou oups ps ps, , , an and d d r re regu gu ula la ato tors rs s.
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It had also been hypothesized that an improvement in glycemic control would be beneficial to reduce the initiation and progression of myocardial dysfunction, reducing the risk of heart failure events. Metabolic control has shown to enhance myocardial contractility parameters, possibly as a result of more efficient myocardial energy substrate use and improved microvascular perfusion. 12 However, results from recent trials have challenged this assumption.
In ACCORD, VADT, and ADAVANCE stricter glycemic control was not associated with a none of the large scale randomized clinical trials evaluating the cardiovascular s sa af afet et ty y of of of n n new ew ew diabetes medications have included heart failure in the primary cardiovascular endpoints and ma many ny ny h h hav av ve e e no no ot in in nc cl clud u ed heart failure events as se se seco co ondary endpoint nt n s. reduced heart failure risk. [7] [8] [9] In the Diabetes Mellitus and Diastolic Dysfunction (DADD) study neither insulin nor oral agents were associated with an improvement in diastolic function despite a reduction in HbA1c. 13 Trials with thiazolidinediones have shown substantially increased heart failure event rates. The use of rosiglitazone and pioglitazone has been associated with more than a 2-fold increased risk of heart failure, including heart failure hospitalizations due to fluid retention and peripheral edema, even in patients without pre-existing left ventricular systolic dysfunction and the risk increased further in patients with a history of heart failure. 5, 6 Recently, the cardiovascular efficacy and safety of the dipeptidyl peptidase-4 (DPP-4) 15 The risk of heart failure hospitalization with saxagliptin was found to be most prominent in the first 12 months of treatment. It was also shown that patients at the greatest risk for hospitalization for heart failure had prior heart failure, elevated baseline levels of NTproBNP, or chronic kidney disease. 15 Patients with or without these risk factors experienced a similar relative risk increase for heart failure hospitalizations with saxagliptin compared to placebo, but the highest absolute risk were observed in those with a greater number of heart failure risk factors. Interestingly treatment with saxagliptin was not associated with increased 14 The primary or e eco co ond nd nda ar ary y y ca ca c r r rdio o ova va vas scular endpoints were simila ar r r be be etween saxaglip ip iptin n an an and d d placebo control during a m me median of 2.1 1 ye ye year rs s fo fo oll ll llow ow ow-u -u -up. p. H H Ho ow owev ev ver, in in this s s t tr rial l l h h hea ear rt r f fai ail lu ur re e h ho os sp pi ita tali li liz za zati tion on ons s we we ere e e pr pros os ospe pe pect ct c iv ivel el ely y y co col lle ec ecte ted d an an a d d th th ther er re e e wa wa w s s a a a 27 27 27% % % re re rela la l t ti tiv ve ve r r ris isk k k in in incr r rea ea e s s se ( ( (ha ha h z z zar rd rd r rat at a io io io 1 1 2 .2 .27 7 7, 9 9 95% % % confidence int nt ter er erva va als ls ls 1 1.0 .0 .07-7 1. 1. 1.51 51 5 , P< P< P<0. 0. 0.00 00 07; 7; 7 0 0 0.7 .7 7% % % ab ab bso so s lu lu l te e e r r ris is sk) k) k) f f for or or h hos os osp p pit it ital al aliz iz izat at a io io on n n fo fo for r r he he h art risk of peripheral edema, adverse event reports for edema, or differences in one year body weight compared to placebo. 15 While baseline NT-proBNP levels were associated with increased risk of heart failure hospitalization, NT-proBNP levels increased only modestly in both the placebo and saxagliptin treated patients, with a slightly greater increase in placebo treated patients.
The findings from SAVOR-TIMI 53 appear consistent with other trials of DPP-4
inhibitors. 16 A recent meta-analysis of 84 4 s s stu tu tudi di dies es s s s sho ho howe we ed d d th that the risk of heart failure wa wa was h higher in patien en e ts t tre re rea at ated with DPP-4 n nhi i ib bitors in co com mp mpar aris i ison on n w wi it ith h h t th thos os se e tr tre ea eat ted wi wi with p p pla a acebo bo bo/a /ac c ctiv iv ve e c co comp mpar ar ra at tor ors s s ( (o (odd dd ds s s ra ra rati i tio o o 1. impact many pathways including those involving cardiac signaling peptides, cardiac collagen turnover enzymes, and the sodium/hydrogen exchanger in the renal proximal tubule. 18 Prior smaller studies with saxagliptin did not suggest an increased risk of weight gain, fluid retention, or new onset heart failure, nor were there signs of excessive volume overload in SAVOR-TIMI 53. 15 Some studies have suggested BNP is a substrate for DPP-4 inhibitors. 18 In SAVOR-TIMI 53, saxagliptin did not increase levels of NT-proBNP. The myocardial effects and energenic consequences of reduced blood and tissue glucose and insulin levels after a prolonged period in which the myocardium had been exposed to elevated glucose and insulin levels might explain the increased risk of heart failure with multiple classes of diabetes medications despite different mechanisms of action. Changes glucose and insulin levels may unfavorably alter the balance of free fatty acid oxidation and glycolysis. Findings from SAVOR-TIMI 53 do not suggest that there was direct myocardial necrosis or inflammation triggered by the medication as there were not significant differences in levels of high sensitivity-troponin T or high sensitivity-C reactive protein with saxagliptin compared to placebo. 15 Some studies have also suggested worsened endothelial function as assessed by flow-mediated dilation with DPP-4 inhibitors. 19 In a 12 month study of the DPP-4 inhibitor vildagliptin in patients with heart failure, New York Heart Association functional class I-III, and reduced left ventricular ejection fraction, the DPP-4 inhibitor increased left ventricular end diastolic volumes, without a change in left ventricular ejection fraction. 20 However, it was preliminarily reported that there were numerically more deaths in the vildagliptin arm (n=11) compared to the placebo arm (n=4), raising additional concerns about safety with DPP-4 inhibitors in patients with established heart failure. 20 Nevertheless further studies are necessary to explore the mechanism(s) which may explain the increased risk of hospitalization for heart failure, as uncovered in SAVOR-TIMI 53 and other studies.
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As noted by the authors, the decision to choose one antihyperglycemic agent versus another must balance the potential benefit in reducing microvascular complications via improved glycemic control together with potential adverse events such as hypoglycemia and heart failure. 15 While the potential benefits of these diabetes medications may become manifest with longerterm follow-up, the risk of heart failure appears to emerge very early.
11 At the population level this increased risk of heart failure may be of significant concern; if a quarter of the 25.8 million individuals with diabetes in the United States were of similar risk profile to those of SAVOR-TIMI 53 and treated with saxagliptin, potentially 45,150 excess heart failure hospitalizations over the next 2 years could result. There exists a compelling need for well-powered randomized clinical trials of diabetes medications with sufficient length of follow-up and that more fully integrate all relevant events, including heart failure, into the primary cardiovascular composite endpoint to more effectively address the crucial questions of net clinical outcomes and the comparative balance of benefit and risk.
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